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ABSTRACT
Human respiratory syncytial virus (HRSV) is a major cause of serious respiratory tract infection. Treatment options include ad-
ministration of ribavirin, a purine analog, although the mechanism of its anti-HRSV activity is unknown.We used transcrip-
tome sequencing (RNA-seq) to investigate the genomemutation frequency and viral mRNA accumulation in HRSV-infected
cells that were left untreated or treated with ribavirin. In the absence of ribavirin, HRSV-specific transcripts accounted for up to
one-third of total RNA reads from the infected-cell RNA population. Ribavirin treatment resulted in a>90% reduction in abun-
dance of viral mRNA reads, while at the same time no such reduction was detected for the abundance of cellular transcripts. The
presented data reveal that ribavirin significantly increases the frequency of HRSV-specific RNAmutations, suggesting a direct
influence on the fidelity of the HRSV polymerase. The presented data show that transitions and transversions occur during
HRSV replication and that these changes occur in hot spots along the HRSV genome. Examination of nucleotide substitution
rates in the viral genome indicated an increase in the frequency of transition but not transversionmutations in the presence of
ribavirin. In addition, our data indicate that in the continuous cell types used and at the time points analyzed, the abundances of
some HRSVmRNAs do not reflect the order in which the mRNAs are transcribed.
IMPORTANCE
Human respiratory syncytial virus (HRSV) is a major pediatric pathogen. Ribavirin can be used in children who are extremely ill
to reduce the amount of virus and to lower the burden of disease. Ribavirin is used as an experimental therapy with other vi-
ruses. The mechanism of action of ribavirin against HRSV is not well understood, although it is thought to increase the mutation
rate of the viral polymerase during replication. To investigate this hypothesis, we used a high-resolution approach that allowed
us to determine the genetic sequence of the virus to a great depth of coverage. We found that ribavirin did not cause a detectable
change in the relative amounts of viral mRNA transcripts. However, we found that ribavirin treatment did indeed cause an in-
crease in the number of mutations, which was associated with a decrease in virus production.
Human respiratory syncytial virus (HRSV) is one of the majorlower respiratory tract pathogens, and almost all infants are
infected at least once within the first 2 years of life (1). Elderly
patients, patients with chronic heart and lung conditions, and
immunocompromised patients are also at risk (2–4). According to
theWorld Health Organization, approximately 60 million people
are infected with HRSV every year, resulting in up to 160,000
deaths (5).
HRSV belongs to the genus Pneumovirus of the family
Paramyxoviridae in the order Mononegavirales (6, 7). The viral
genome consists of a nonsegmented, 15-kb RNA of negative
polarity that encodes 10 mRNAs and 11 proteins. As with all the
members of the Mononegavirales, the genomic RNA of HRSV is
tightly bound by the viral nucleoprotein (N) and maintained as a
helicalN-RNA ribonucleoprotein (RNP) complex (8). TheRNP is
used as a template for transcription and replication by the RNA-
dependent RNA polymerase (RdRp) complex, which consists of
the large subunit (L) and its cofactor phosphoprotein (P) (9, 10).
Whereas N, P, and L are sufficient to mediate viral replication,
transcription activity also requires the M2-1 protein, which func-
tions as an RdRp processivity cofactor (11, 12). The specific rec-
ognition of the viral N-RNA complex by the RdRp constitutes a
prerequisite for viral transcription and replication. This recogni-
tion is mediated by the P protein (13), which interacts with the L,
N, and M2-1 proteins.
To perform transcription and replication, the RdRp engages
with promoter sequences that lie at the 3= ends of the genome and
antigenome RNAs (14). The 44-nucleotide (nt) leader (Le) pro-
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moter region at the 3= end of the genome is responsible for direct-
ing initiation of mRNA transcription and antigenome synthesis.
The 155-nt trailer complement promoter at the 3= end of the
antigenome directs genome RNA synthesis. The 10 viral genes are
arranged sequentially (3=-NS1, NS2, N, P, M, SH, G, F, M2, and
L-5=), and each is flanked by conserved gene start (GS) and gene
end (GE) sequences, which control the RdRp during transcription
(15, 16). Each gene is separated from the preceding one by an
intergenic region of variable length. The RdRp initiates RNA syn-
thesis at the leader promoter and then progresses along the length
of the genome (16–18). The RdRp is able to generate subgenomic
mRNAs by responding to the GE and GS signals at the gene junc-
tions. When it reaches a GE signal, the RdRp polyadenylates and
releases the nascent mRNA of the upstream gene. It then reiniti-
ates mRNA synthesis of the subsequent gene at the next GS signal.
There is a tendency for the RdRp to cease transcription at the gene
junctions, and on rare occasions, the transcribing RdRp fails to
respond to a GE signal, resulting in synthesis of a polycistronic
mRNA that contains an intergenic region. Because the RdRp can
initiate transcription only at the 3= end of the genome and can
disengage transcription at the gene junctions, it is expected that
there is a gradient of expression of HRSV mRNAs, with genes at
the 3= end of the genome (e.g., NS1 and NS2) being transcribed
more frequently than genes at the 5= end of the genome (e.g., the L
gene), and indeed this has been shown to be the case in vitro (19).
Ribavirin is the only therapeutic approved by the Food and
Drug Administration (FDA) for the treatment of HRSV (20).
Clinically, ribavirin is used in immunocompromised and/or
transplant and acute high-risk groups infected with HRSV (for
example, see reference 21). Ribavirin has broad-spectrum antivi-
ral properties and is also used clinically in the treatment of infec-
tions with hepatitis E virus (HEV) (22) and hepatitis C virus
(HCV) (23) and for diseases caused by several hemorrhagic fever
viruses (for example, see reference 24). Ribavirin is a purine nu-
cleoside analog which is metabolized to ribavirin triphosphate by
cellular kinases (25, 26). Ribavirin (and its phosphorylated deriv-
atives) has been shown to havemultiple effects that may enable its
broad-spectrum antiviral activity, including, among others, en-
hancement of interferon-stimulated gene expression; inhibition
of the cellular enzyme inosine 5=-monophosphate dehydrogenase
(IMPDH), which is required for maintenance of the intracellular
pool of GTP; chain termination during viral RNA synthesis; inhi-
bition of 5=-methylguanosine cap formation; and accumulation of
mutations in viral genomes (reviewed in references 27 to 29). In
the latter case, mutations accumulate because ribavirin is capable
of base pairing equally well with cytidine and uridine, resulting in
an increase of the rate of C-to-U and G-to-A transitions (30–32).
This results in hypermutation, which can be lethal to virus biology
through error catastrophe. This mechanism of action has been
proposed for and supported by experimental data in vitro for po-
liovirus (33) and HCV and in vivo for HCV (23).
Previous studies have investigated the effect of IMPDH inhibi-
tion during HRSV infection (34, 35), but the effect that ribavirin
might have on the fidelity of HRSVRNAs or the stability of result-
ing mRNA transcripts has not previously been examined. To in-
vestigate the influence of ribavirin on HRSV RNA synthesis, we
used high-resolution transcriptome sequencing (RNA-seq). Mi-
nor variant analysis allowed us to assess the effect of ribavirin on
the frequency of mutations in the HRSV genome. The addition of
ribavirin resulted in a decrease in the abundance of viral RNA and
a modest increase in the frequency of transition but not transver-
sionmutations, suggesting a direct influence on polymerase fidel-
ity. In addition, we found that in both the absence and presence of
ribavirin, the cumulative abundances of viral mRNAs at the two
time points analyzed did not follow the transcription gradient of
mRNA synthesis, contrary to what was anticipated.
MATERIALS AND METHODS
Cells and virus.HEp-2 cells were grown at 37°C with 5%CO2 in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 10% (vol/
vol) fetal bovine serum (FBS) and 1% (vol/vol) penicillin-streptomycin.
The HRSV-A2 strain was used in this study and was purified through a
sucrose gradient prior to the infection experiments. The virus was not
plaque purified and thus was heterogeneous.
Antiviral ribavirin. Ribavirin was obtained from Sigma. A 1 mM
stock was preprepared in dimethyl sulfoxide (DMSO) and added at either
6 or 24 h postinfection (hpi). MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] assays were performed to ensure that
cell viability was not affected at the working concentration.
Immunofluorescence. Coverslip-adhered cell monolayers were fixed
with paraformaldehyde and made permeable with phosphate-buffered
saline (PBS) containing 0.1% (vol/vol) Triton before adding a fluorescein
isothiocyanate (FITC)-conjugated anti-HRSV-A2 specific primary anti-
body from Abcam (ab20391).
Western blotting. Cell lysates were prepared, and the total protein
concentration was determined by bicinchoninic acid (BCA) assay
(Pierce). Proteins (5g/l) were resolved by 7.5% SDS-PAGE and trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Millipore) by
use of a Bio-Rad semidry transfer apparatus.
Determinationof50%tissue culture infectivedose (TCID50).HEp-2
cells were seeded in 24-well plates at a density of 5 104 in 1 ml growth
medium in order to have80% confluence following overnight incuba-
tion. The medium was aspirated from the wells after 24 h, and cells were
washed twice with PBS. Extracellular and intracellular preparations (200
l) were added to 4 wells of 96-well plates (HEp-2 cells at 80% conflu-
ence). The plates were incubated for 2 h, with shaking every 20 min. The
inoculum was removed, and 200 l of maintenance medium was added
and incubated for 7 days. At 7 days postinfection, all plates were exam-
ined, and the number of wells of each dilution that were positive for an
HRSV cytopathic effect (CPE) (syncytium formation) was counted and
calculated by using the Kärber algorithm.
Determining cell viability. Cell viability was determined by using a
colorimetric MTT assay. HEp-2 cells were seeded in triplicate in 96-well
plates at a density of 1 104 to ensure 70% confluence at 24 h, after which
all wells were washed twice with 1 PBS. Ribavirin was then added to
wells at different concentrations (low to high) and incubated for 24 h at
37°C. Next, the wells were washed twice with 1 PBS. MTT (0.024 g;
Sigma) was prepared in 10 ml of medium (DMEM plus 10% FBS for
HEp-2 cells) and warmed to 37°C. The MTT was dissolved and filtered,
100 l was added to each well, and the plate was incubated for 50 min at
37°C. After this incubation, the MTT was removed, 100 l of DMSO was
added andmixed, and the color wasmeasured at 570 nmby use of a Tecan
reader.
RNA extraction andRNA sequencing.Total RNAwas extracted from
HEp-2 cells (in triplicate) by use of a Qiagen RNeasy minikit. The RNA
concentration was measured by the Qubit RNA BR assay. Agarose gel
electrophoresis with ethidium bromide (EtBr) staining was used to visu-
alize RNA in order to check the quality of each RNA sample. cDNA was
synthesized from RNA via reverse transcription in order to check the
amplification by using an RdRp chain reaction. Samples were quality
checked for integrity (Bioanalyzer RNA picochip) and quantity (Qubit
RNA kit). After assessing that the RNA quality was good, with RNA integ-
rity number (RIN) values of 9, the samples were subjected to poly(A)
selection by use of a Dynabeads mRNA purification kit (Life Technolo-
gies). In this case, 15 l of beads per sample was washed with binding
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buffer (2) and resuspended in 30 l of 2 bead buffer. Samples were
made up to 30 l and heated to 65°C for 5 min to remove any secondary
structure. Samples were mixed with the beads on a rotator for 5 min at
room temperature. After collecting the beads on aMagnetic Particle Con-
centrator (MPC), the beads were washed twice with wash buffer, with
removal of all traces after each wash step. Twelve microliters of water was
added to the beads for elution, which was achieved by heating the sample
at 70°C for 2min and retrieving the supernatant containing the RNA. This
was assessed for rRNA on a RNA picochip.
The twice-selected material was all used as input for ScriptSeq assay
(Epicentre). Samples were treated per the manufacturer’s protocol. Sam-
ples weremixed with primer and fragmentation buffer, heated at 85°C for
5 min, and placed on ice. Samples were converted to cDNA and purified
with Ampure XP. Samples were mixed with bar-coded primers and am-
plified with 15 PCR cycles. The libraries were purified with Ampure XP
and assessed by use of a Bioanalyzer and an HS DNA kit, and the quantity
was determined by use of aQubit DNAHS kit. Samples were pooled on an
equimolar basis for a single lane.
The quantity and quality of the final pool were assessed using a Qubit
kit (Invitrogen) and a Bioanalyzer (Agilent) and then quantitative PCR,
using a Kapa library quantification kit on a Roche LC480II Light Cycler
machine according to the manufacturer’s instructions. The template
DNA was denatured according to the protocol described in the Illumina
cBot user guide and loaded at 9 pM. To improve the sequencing quality
control, 1% PhiX174 was spiked into the sample. Sequencing was carried
out on an Illumina HiSeq 2000 instrument with version 3 chemistry,
generating 100-bp paired-end reads.
For each time point, the sequence reads weremapped to theHRSV-A2
genome by using Bowtie2. For each alignment to the HRSV genome, the
output BAM files were further analyzed using QuasiRecomb (36). While
Bowtie2 aligned more than 1 million reads to the HRSV genome, we
selected 1million alignments at random.We used the coverage option for
QuasiRecomb (command line java  XX:NewRatio  9  Xms2G 
Xmx10G  jar QuasiRecomb.jar  i reads.sam  coverage) and then
parsed the output files with in-house software written in Perl that deter-
mined themost abundant nucleotide for each position (i.e., the consensus
nucleotide) and reported the frequency of use for the other three nucleo-
tides, as described previously (37).
RESULTS
Various studies have revealed the inhibitory nature of ribavirin on
HRSV in vitro. For example, addition of ribavirin at2, 0, and 1
hpi resulted in a 95% plaque reduction (38); however, the mech-
anism of this inhibition is unclear.
RNA sequencing has not been applied at a high read depth to
studyHRSV replication and transcription, and it provides an ideal
approach to study the potential mutagenic effect of ribavirin on
HRSV genome biology. We utilized our recently described pipe-
line (based on the Galaxy platform), which was used to generate
consensus genomes and maps of minor variants to study Ebola
virus evolution in a guinea pig model (39) and in patient samples
taken from the 2014-2015 West African outbreak (37). These
studies indicated that a greater read depth during RNA-seq pro-
vided more accurate base calling on the consensus genome and
maps of minor variants.
To provide sufficient viral RNA for sequencing and to balance
thiswith infectivity and cell viability (throughboth treatmentwith
ribavirin and infection with HRSV), several optimization experi-
ments were performed. The concentration of ribavirin used was
based on previous literature, and anMTT assay was used to estab-
lish cell viability versus toxicity in HEp-2 cells (Fig. 1A). These
analyses, together with concentrations previously used in the lit-
erature, suggested that a concentration of 500 M would be tol-
erated and provide antiviral activity. Next, we investigated four
different viral multiplicities of infection (MOIs) (0.005, 0.05, 0.5,
and 5) in the absence and presence of 500M ribavirin by using a
fluorescence-based assay system to visualize HRSV-infected cells
(Fig. 1B). These data indicated that at an MOI of 0.5 and in the
presence of 500 M ribavirin, there was a visible decrease in the
number of infected cells compared to untreated cells. At a lower
MOI, fewer cells were infected (therefore providing less RNA for
robust sequencing). The inhibitory action of ribavirin on the out-
put of HRSV progeny was confirmed using the TCID50. This in-
dicated that the amount of progeny virus was reduced approxi-
mately 5 log in the presence of 500 M ribavirin compared to
either untreated infected cells or infected cells treated with the
DMSO vehicle.
Next, the effects of ribavirin treatment at6, 0, 6, 12, 18, and
24 hpi on HRSV biology were compared (Fig. 2). For treatment
with ribavirin at6, 0, 6, 12, and 18 hpi, an assay point of 24 hpi
was used, and for treatment with ribavirin at 24 hpi, an assay point
of 48 hpi was used. Immunofluorescence, TCID50 determination,
and Western blotting were used to evaluate virus-infected cells
(Fig. 2A), viral progeny production (Fig. 2B), and viral protein
abundance (Fig. 2C), respectively. On the basis of these findings,
in order to ensure sufficient read depth and to derive informa-
tion on sequence changes, the following time points were cho-
sen for further analysis: (i) ribavirin added at 6 hpi and RNA
harvested at 24 hpi and (ii) ribavirin added at 24 hpi and RNA
harvested at 48 hpi.
Determining the abundances of viral mRNAs in HRSV-in-
fected cells by using RNA-seq. RNA-seq was used to measure the
abundances of poly(A)-selected viral mRNAs at the two different
time points in both untreated and ribavirin-treated HEp-2 cells.
RNA-seq analysis for the two different time points indicated that
in untreated HEp-2 cells at 24 and 48 hpi, 19.8% and 10.53% of
total reads mapped to HRSV RNA (Table 1), corresponding to
6,162,832 and 3,810,092 reads, respectively.HRSV transcripts also
reached a high level in A549 cells, in this case representing 34.72%
of the total reads (Table 1), for a total of 14,105,224 reads.
From the RNA-seq data, we calculated the relative abundances
of each viralmRNAat 24 and 48 hpi in the absence and presence of
ribavirin treatment by using the numbers of reads mapping to
each gene. We were not able to discriminate monocistronic viral
mRNAs from polycistronic RNAs, although the abundances of
polycistronic readthrough products are generally low in HRSV
infections (40). The data indicated that as a proportion of total
reads, the amount of viral RNA decreased in the presence of riba-
virin (Table 1). The accumulation of each mRNA in an infected
cell might be expected to reflect the order of genes on the genome,
such that the relative abundance of different gene transcripts
would correlatewith gene position relative to the 3= end.However,
for the two timepoints examined, the data showed thatwhile there
was a general trend of abundance correlating with gene order,
there were exceptions (Fig. 3A). For example, as expected, the L
mRNA was the least abundant transcription product (Fig. 3A),
but the mRNA encoding the G protein appeared to be the most
abundant mRNA at both time points in both the absence and
presence of ribavirin. This observation suggests that factors other
than gene order may be able to influence HRSV mRNA abun-
dance in cells, in particular for the G mRNA. Importantly, the
profiles of relative viral mRNA abundance were equivalent for
untreated and ribavirin-treated infected HEp-2 cells, suggesting
Aljabr et al.
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that ribavirin did not impinge upon the overall program of HRSV
transcription per se.
We hypothesized that if viral mRNA transcript levels are gov-
erned in part bymRNA stability, the profile of relative levelsmight
be different in different cell types. Therefore, we investigated the
abundances of viral mRNAs in HRSV-infected A549 cells at 24
hpi. In this instance, 34.72% of the total reads mapped to the
HRSVmRNAs (Table 1), for a total of 14,105,224 reads. Again, the
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data indicated that the abundances of viral mRNAs at this time
point and in this cell type did not correspond to the predicted
linear gradient (Fig. 3A).
To investigate this further, as an exemplar, the RNA-seq data
for HRSV in HEp-2 cells at 24 hpi were further processed to in-
clude only propermate pair reads, where both reads weremapped
and correctly orientated with respect to each other. The seed
length was increased from 28 to 35 nt. The maximum number of
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mismatches was reduced to 1. One effect of this was to bias the
reads toward those that matched the consensus sequence. These
data again indicated that the L mRNA was the least abundant
HRSV transcript (Fig. 3B); however, the differences in the other
gene products were less pronounced, with P and G transcripts
being almost equivalent (Fig. 3B).
Readthrough at gene junctions correlates with previous sub-
genomic replicon data. The data also provided ameasurement of
readthrough, which allowed a direct comparison to previously
published results. This was done by comparing the average num-
ber of fragments per kilobase of exon per million fragments
mapped (FPKM) in the intergenic region to the total virus FPKM.
From this, the percentages of readthrough between adjacent genes
were calculated, with the following results: 30% for NS1-NS2,
13% forNS2-N, 10% forN-P, 4% for P-M, 21% forM-SH, 4% for
SH-G, 8% for G-F, and 11% for F-M2. For the gene junctions
examined, this pattern of relative readthrough efficiencies corre-
lates with data examining the transcription termination efficien-
cies of gene junctions in the context of subgenomic replicons (40).
For example, in both studies, data indicated that the SH-G gene
junction terminated transcriptionswith the greatest efficiency and
produced low levels of readthrough transcripts, whereas the NS1-
NS2 gene junction had the highest level of readthrough (40).
RNA-seq analysis revealed an increase in the frequency of
transition but not transversion mutations in the presence of
ribavirin. To access the frequency of potential nucleotide substi-
tution in the different populations, the QuasiRecomb algorithm
(36) was used to obtain coverage and data on the proportion of
each nucleotide used at any given location on the genome. The
results were further processed by an in-house script to determine
which nucleotide was the most abundant at each nucleotide posi-
tion and how frequently any of the other three nucleotides were
used at that position. We used a similar approach to derive con-
sensus genomes and examine nucleotide variation that corre-
sponded with increases in virulence of Ebola virus in a guinea pig
model of infection (39), to measure Ebola virus evolution during
the 2014-2015 West African outbreak (37), and to investigate in-
fections of human and bat cells withHendra virus (41). These data
are displayed as frequencies of use of minor nucleotides along the
genome (Fig. 4). For example, in the case of HRSV assayed at 24
hpi, there were 13 nucleotide positions that had a substitution in
30% or more of the sequence reads that mapped across that loca-
tion (Fig. 4A). On first inspection, the nucleotide substitution
frequency in HRSV RNA isolated from cells that had been treated
with ribavirin at 6 hpi (assay point at 24 hpi) seemed large, espe-
cially in the L gene sequence (Fig. 4B). However, further inspec-
tion of the data revealed that given the 166-fold decrease in map-
pable reads at this assay point, there were relatively few quality
reads, and the apparent nucleotide frequency variation decreased
when lower-quality reads were removed (Fig. 4C). We also artifi-
cially reduced the number of mapped reads obtained without
ribavirin to the levels seen when we examined cells treated with
ribavirin at 6 hpi (data not shown).When we examined the set for
minor variants, we saw a similar pattern of nucleotide variation
(data not shown), confirming our supposition that compared to
the larger number of mappable reads (Fig. 4D), the small number
of mappable reads (Fig. 4E) led to an apparent increase in varia-
tion which cannot be attributed to ribavirin treatment.
Analysis of the sequence data obtained when ribavirin was
added at 24 hpi and viral RNA was analyzed at 48 hpi provided
higher-quality reads. For the control untreated HRSV infection,
therewere 8 nucleotide positions that had a substitution in 30%or
more of the sequence reads that mapped across that location (Fig.
4F). For theHRSV infection inwhich ribavirinwas added at 24 hpi
and the nucleotide sequence was analyzed at 48 hpi, there were 5
nucleotide substitutions that were present in 30% or more of the
sequence reads that mapped across that location (Fig. 4G).
As described in the introduction, ribavirin treatment might be
expected to result in an increase in transition mutations specifi-
cally. To distinguish this effect, analysis of mutations was per-
formed using Bioedit Textpad and Excel software. Initially, all
transitions and transversions were scored and given a binary iden-
tification. Transversions were also analyzed as an internal control
to investigate whether the frequency of any mutation increased in
the presence of ribavirin. Subsequently, a sliding window of 500
nucleotides was arbitrarily chosen and was moved across the full
length of the reference sequence by increments of 500 nucleotides.
In each step, the numbers of transversions and transitions among
the minor sequence quasispecies were determined (Fig. 5). The
data indicated that transition mutations significantly increased in
the presence of ribavirin compared to those in the untreated con-
trol. The frequency of transversionswas not significantly different.
Reflecting this, the ratio of transitions to transversions was signif-
icantly higher in ribavirin-treated infected cells than in untreated
infected cells. There was more experimental noise associated with
the analysis of transitions for cells treated with ribavirin at 6 hpi
(assay point at 24 hpi) than for cells with ribavirin added at 24 hpi
(assay point at 48 hpi). We attribute this to the lower-quality se-
quence reads, and the comparative data shown in Fig. 5 are based
on sequence reads obtained with the more abundant transcripts
produced from the first half of the genome.
These results were also compared to data obtained from cells
treated with 17-(allylamino)-17-demethoxygeldanamycin (17-
AAG) as a control. Treatment of infected cells with 17-AAG in-
hibits the chaperone activity of HSP90 and results in destabiliza-
tion of the HRSV L protein (42). Thus, 17-AAG acts indirectly as
an inhibitor of RdRp accumulation (rather than activity) and has
been shown to have an antiviral effect onHRSV (42–44) and other
negative-strand RNA viruses (45). In the present study, the nucle-
otide substitution frequency was analyzed at 24 hpi. At this time
point, there were 8 nucleotide positions that had a substitution in
30% or more of the sequence reads that mapped across that loca-
TABLE 1 Numbers and proportions of sequence reads mapping to the
HRSV genome out of the total number of sequence reads
Cell
line Conditions
No. of reads
mapping to
the HRSV
genome
Total no.
of reads
% of
total
reads
HEp-2 HRSV at 24 hpi 6,162,832 31,118,416 19.8
HRSV ribavirin
at 24 hpi
21,350 32,769,666 0.07
HRSV at 48 hpi 3,810,092 36,182,362 10.53
HRSV ribavirin
at 48 hpi
436,172 44,545,058 0.98
A549 HRSV at 24 hpi 14,105,224 40,622,791 34.72
HRSV 17-AAG
at 24 hpi
1,549,050 37,493,536 4.13
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tion in the untreated control (Fig. 6). For the HRSV infection in
which 17-AAG treatment was started at 6 hpi and the HRSV se-
quence was analyzed at 24 hpi, this resulted in a 9-fold decrease in
mappable reads to the HRSV genome (Table 1); there were 9 nu-
cleotide positions that had a substitution in 30% or more of the
sequence reads that mapped across that location (Fig. 6). There
was no evidence that 17-AAG caused an increase in the frequency
of transitions or transversions in HRSV-infected cells (Fig. 5).
Transition and transversion substitutions occur in clusters
along HRSV RNA. Interestingly, analysis of the positions and fre-
quencies of the transition and transversion mutations along the
HRSV genome, for virus either left untreated or treated with riba-
virin, suggested that these background substitutions did not occur
with an even distribution and instead clustered in discrete hot
spots (Fig. 7). These hot spots were equivalent for HRSV grown in
either HEp-2 or A549 cells, indicating that this observation was
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FIG 3 (A) Analysis of the abundances of viral mRNAs in HEp-2 or A549 cells infected with HRSV at different time points and in HEp-2 cells in the absence or
presence of ribavirin. The viral mRNA abundances are shown in order of the particular genes along the HRSV genome, listed from the 3= to the 5= end, and also
in the order in which the particular genes are transcribed. Abundance is shown in fragments per kilobase of exon per million fragments mapped (FPKM). (B)
RNA-seq data for HEp-2 cells at 24 hpi were further processed to include only proper mate pair reads, where both reads were mapped and correctly orientated
with respect to each other. The seed length was increased from 28 to 35 nt. Themaximumnumber ofmismatches was reduced to 1. The horizontal lines trace the
average abundances of mapped reads for the different genes.
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FIG 4 Analysis of depth of coverage and minor variation along the HRSV genome in the presence or absence of RBV. In each part, the nucleotide position is
indicated along the x axis. Charts illustratingminor variation show the proportion ofminor nucleotide calls at each nucleotide as a fraction of 1; thus, a bar height
of 0.4 indicates that at that nucleotide position, some 40% of the sequence reads indicated an alternate base relative to the consensus. Charts illustrating coverage
depth are simple plots of the depth of sequence coverage at each nucleotide position. (A) Locations of minor variant base calls for HRSVmRNAmapped to the
HRSV genome at 24 h postinfection. (B) Locations ofminor variant base calls forHRSVmRNAmapped to theHRSV genome at 24 h postinfection for infections
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not dependent on these two cell types. Some of these hot spots
were located in the intergenic regions, but somewere also found in
coding regions. There was no significant increase in transition or
transversion substitutions in HRSV-infected cells treated with
DMSO (Fig. 5), which was the ribavirin solvent. However, there
was an increase in the number of transition mutations between
(and within) hot spots with ribavirin treatment. From this analy-
sis, it is clear that nucleotide changes in the viral genomedue to the
action of ribavirin occur both in these clusters and between these
clusters (Fig. 7). The data also indicate that, in general, there is a
greater frequency of transition and transversion substitutions
within noncoding regions than within coding regions (Fig. 8).
DISCUSSION
For the first time, we have used RNA-seq at a high resolution to
investigate HRSV RNA synthesis and to analyze the effects of a
widely used and reportedly broad-spectrum antiviral drug, riba-
virin, on infected-cell RNAaccumulation and viral RNAmutation
frequency. RNA-seq analysis revealed that in the absence of riba-
virin, HRSV-specific RNAs formed up to one-third of all RNA
reads, suggesting a remarkable domination of the cellular RNA
pool, at least in cell culture models. Our analysis of sequencing
data to generate minor variants was indeed capped at 1 million
reads mapping to the HRSV genome.
Ribavirin treatment of HRSV-infected cells resulted in de-
creases in progeny virus and overall levels of viral RNA as deter-
mined by the number of sequence reads thatmapped to theHRSV
genome (Table 1). While this reduction in the number of reads
mapping to the HRSV genome in proportion to the total number
of reads obtained could be explained by an increase in cellular
mRNA levels caused by ribavirin treatment, the data we have do
not support this conclusion. This would require a significant
(10-fold) and across-the-board increase (and in just the same
genes detected in the ribavirin-only control samples) in the total
amount of mRNA in the cell. This would be unusual for either
ribavirin treatment or HRSV infection. In addition, we saw no
evidence of increases in total RNA extracted from the cells treated
solely with ribavirin.
where ribavirin was added to the medium at 6 h postinfection, using the same mapping pipeline as that used for panel A. (C) Analysis of the same raw sequence
data as in panel B, but with low-quality sequence reads removed (e.g., all reads with a MAPping Quality (MAPQ) value value of	11 and a mapped read length
of	50 bases). (D) Depth of coverage of sequence data for HRSVmRNAmapped to the HRSV genome at 24 h postinfection, with the locations of HRSV genes
indicated. (E) Depth of coverage of sequence data for HRSV mRNAmapped to the HRSV genome at 24 h postinfection for infections with ribavirin added at 6
h postinfection. Note the change in scale on the y axis. (F) Locations of minor variant base calls for HRSV mRNA mapped to the HRSV genome at 48 h
postinfection. (G) Locations of minor variant base calls for HRSVmRNAmapped to the HRSV genome at 48 h postinfection for infections where ribavirin was
added to the medium at 24 h postinfection, using the same mapping pipeline as that used for panel A.
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FIG 5 Transition and transversion analyses of each of the culture conditions. The analysis was implemented using a 500-nucleotide sliding window across the
genome. The area coding for the polymerase gene was not included in the analysis because the sequencing depth for this genomic region was much lower. Each
box plot indicates the mean value, the 25th and 75th percentiles, and the 95% confidence interval (CI) of the mean. For comparisons, the paired t test was
implemented using the Prism software package (GraphPad). (A) Purine-pyrimidine transversions; (B) purine-purine and pyrimidine-pyrimidine transitions;
(C) transitions and transversions; (D) G-to-A permutations (E); A-to-G permutations; (F) C-to-U permutations. The analysis was also performed using a
100-nucleotide sliding window (data not shown), and the results were similar.
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Our analysis indicated that the frequencies of transitions, but
not transversions, in the HRSV genome were significantly differ-
ent between infected cells treated with ribavirin and untreated
infected cells. No increase in nucleotide transitions or transver-
sions in the HRSV sequence was associated with treatment of in-
fected cells with 17-AAG, an inhibitor of HSP90 (Fig. 5) and
HRSV polymerase accumulation and function (42). There was an
approximately 1.5-fold increase in the recorded frequency of tran-
sitions on HRSV RNA in infected cells treated with ribavirin at 24
hpi compared to the untreated control cells (Fig. 5). This is less
than the 4.4-fold increase in the frequency of transitions associ-
ated with the treatment of poliovirus-infected cells with 400 M
ribavirin (33), and the reasons for this are unclear. In the poliovi-
rus study, cells were pretreated with ribavirin and the drug was
maintained throughout the 6-h infection, whereas in this study
ribavirin was not added to the HRSV-infected cells until either 6
or 24 hpi. Alternatively, or in addition, it might be that the HRSV
RdRp ismore stringent than that of poliovirus, possibly due to the
2-fold longer length of the HRSV genome. In this scenario, the
HRSV RdRp might better discriminate against ribavirin triphos-
phate, resulting in reduced incorporation and thus a lower muta-
tion rate. Regardless, elevations inmutation frequencies of as little
as 2-fold have been proposed to lead to fitness losses and extinc-
tions of large RNA virus populations in cell culture and animal
models of infection (46), so the 1.5-fold increase in mutation fre-
quency observed here could explain why ribavirin treatment re-
sulted in reduced HRSV-specific RNA levels and progeny virus
(Fig. 1 and 2). While these results strongly suggest that the anti-
HRSV action of ribavirin is through direct incorporation into nas-
cent RNA by the viral polymerase, we cannot exclude the possi-
FIG 6 Analysis of minor variation along the HRSV genome in the presence or absence of 17-AAG. In each part, the nucleotide position is indicated along the x
axis. As described in the legend to Fig. 4, theminor variation shows the proportion ofminor nucleotide calls at each nucleotide as a fraction of 1; thus, a bar height
of 0.4 indicates that at that nucleotide position, some 40% of the sequence reads indicated an alternate base relative to the consensus. (A) Locations of minor
variant base calls for HRSVmRNAmapped to the HRSV genome at 24 h postinfection in A549 cells. (B) Locations of minor variant base calls for HRSVmRNA
mapped to the HRSV genome at 24 h postinfection for infections where 17-AAG was added to the medium at 6 h postinfection in A549 cells, using the same
mapping pipeline as that used for panel A. Both data sets were generated independently of those analyzed in Fig. 4.
FIG 7 Representative analysis of transitions (full circles) and transversions (open diamonds) resulting from theminor nucleotide variants at each position of the
HRSV genome with the different treatment regimens. For each condition, the consensus sequence (con) is shown on the first line. The following four lines
represent each of the four nucleotides found asminor variants. The cutoff value was 0.5%, and the region of the genome shown is indicated by the bold numbers
at the top.
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bility that other proposed activities, such as reduction of the GTP
pool, also contribute to reduced viral growth and HRSV-specific
RNAs, although ribavirin did not affect the overall levels of cellu-
lar mRNA (Table 1).
As noted, the read depth of viral RNA was much lower when
infected cells were treated with ribavirin at 6 hpi than when in-
fected cells were treated with ribavirin at 24 hpi. In order to com-
pare the nucleotide substitution frequencies under these two ex-
perimental conditions, we used data from the 3=-proximal half of
theHRSV genome. This is because themajority of the 5=-proximal
portion of the genome encodes the L mRNA, which is the least
abundant transcript and subsequently has even fewer sequence
reads mapping to it. The error rate of viral RdRps is estimated to
be between 1.5 103 bp1 (bacteriophage Q
) and 7.2 105
bp1 (influenza virus) (47). This relaxed fidelity of RdRp activity
is an important feature of RNA virus biology, providing a source
of sequence diversity that can allow virus quasispecies to form,
enabling the virus to adapt successfully to changing environments.
However, this inherent RdRp error rate can also be detrimental to
virus biology and lead to the generation of nonviable templates
that reduce overall viral fitness. The term “error catastrophe” has
been used to describe the outcome of an RdRp error rate at which
too many nonviable templates are generated and a virus popula-
tion becomes unsustainable, and it is believed that many viral
RdRps operate close to this threshold (48, 49). Although the
length of the HRSV genome is only1.5 times longer than that of
HCV or poliovirus, a 50% increase in the frequency of transition
mutations appears to be sufficient to cause a loss of viable virus.
Interestingly, the analysis indicated that transitions and trans-
versions occurred in clusters along the HRSV RNA genome (Fig.
7), and this was the same for viruses grown in different cell lines
(e.g., HEp-2 and A549) and under a variety of different treatment
conditions (e.g., in the presence of 17-AAG). Some of these clus-
ters localized to the intergenic regions, and one possibility for this
is the known tolerance for sequence changes within this region of
the HRSV genome, as reflected in the differences between the
frequencies of transition and transversion events between the cod-
ing and noncoding sequences (Fig. 8). It is worth noting that these
are the positions where such minor variants can occur but that
these do not reflect the average consensus sequence. Analysis in-
dicated that treatment with ribavirin increased the frequency of
transition mutations in both the coding and noncoding regions
(Fig. 8).
The data also indicated a preponderance of A-to-G changes in
the minor variants, which is a characteristic of adenosine deami-
nases acting on RNA (ADAR), a modification which, depending
on the virus, has been reported to have both antiviral and proviral
activities (50). Genome-wide association studies have shown an
increase in ADAR transcripts during HRSV infection in a mouse
model (51). Escape mutant analysis with antibodies specific for
the G protein suggested that the G gene could potentially bemod-
ified by ADAR activity (52).
Analysis of the abundances of HRSV mRNAs at the two time
points analyzed indicated that they did not reflect the linear gra-
dient that is predicted by the generally accepted and long-standing
model for polar and sequential transcription of negative-strand
RNA viruses (Fig. 3). We used several different algorithms to an-
alyze the RNA-seq data, and each of these indicated that the abun-
dances of viral mRNAs in the cell at these specific time points did
not follow a precise linear gradient. For the final data analysis
shown in Fig. 3, we manually calculated the number of fragments
per kilobase of gene per million bases mapped. Even a very con-
servative analysis of the RNA-seq data indicated a nonpolar abun-
dance of viral transcripts (Fig. 3B).Given that there are very strong
data to show that the HRSV RdRp cannot enter the template in-
ternally (17) and that in an in vitro transcription assay the amount
of each transcript reflects the position of the gene on the genome
(19), this result indicates that while gene order is a principle de-
terminant of transcript abundance, it is not the only factor, with
mRNA stability likely making an important contribution to rela-
tivemRNA levels. Importantly with respect to this study, ribavirin
had no effect on the relative abundances of the 10 sequentially
transcribed HRSV transcripts (Fig. 3). Our current findings also
suggest that ribavirin has no detectable influence on RNA synthe-
sis processes that may affect transcript stability. These include
RNA processing events, such as 5= capping and poly(A) tail addi-
tion. The RNA-seq approach may provide a bias toward the re-
cording of different mRNA abundances, although the data indi-
cated that the percentages of readthrough of HRSV transcripts
followed the same pattern as that described using alternative ap-
proaches (40).
In a study using RNA-seq to measure viral mRNA abundance,
a similar result was recently described for the analysis of Hendra
virusmRNA in infected human or bat cells (41). Similar toHRSV,
Hendra virus is amember of theParamyxoviridae family, and both
viruses share similar genome architectures and replication and
expression strategies. The order of genes along the Hendra virus
genome (3= to 5=) is N, P, M, F, G, and L. In the analysis of either
human or bat cells infected with Hendra virus, there was a steep
decline in the abundance of transcripts at theM-F gene boundary,
and the mRNA encoding the G protein was more abundant than
the preceding mRNA, encoding the F protein (41).
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FIG 8 Analysis of transitions and transversions in coding and noncoding regions of the HRSV genome with the different treatment regimens.
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In summary, RNA-seq analysis was used to investigate HRSV
RNA synthesis in infected cells and cells treatedwith ribavirin. The
data indicated that both transition and transversion mutations
occurred in clusters along the HRSV genome. The frequency of
transitionswas increased inHRSV-infected cells treatedwith riba-
virin and correlated with reductions in the abundance of viral
RNA and in progeny virus, consistent with a loss of viral fitness.
ACKNOWLEDGMENTS
This research was supported by aMedical Research Council (MRC) proj-
ect grant (MR/K000276/1) awarded to J.N.B. and J.A.H. that directly sup-
portedW.W. andD.C.M.W.A. is supported by theMinistry of Education,
Kingdom of Saudi Arabia. The work was also supported by the National
Institute for Health Research Health Protection Research Unit (NIHR
HPRU) in Emerging and Zoonotic Infections at the University of Liver-
pool, in partnership with Public Health England (PHE) and the Liverpool
School of Tropical Medicine.
The views expressed are those of the authors and not necessarily those
of the NHS, the NIHR, the Department of Health, or Public Health Eng-
land.
We declare that we have no competing interests, apart from R.F., who
has sponsored research agreements with AstraZeneca and Alios-
Biopharma, although neither of these entities supported or influenced the
work described in this paper.
D.A.M., R.F., and J.N.B. acknowledge the personal support through-
out their careers from Craig R. Pringle, who recently passed away after a
lifetime of valuable contributions to RSV research.
REFERENCES
1. Collins PL, GrahamBS. 2008. Viral and host factors in human respiratory
syncytial virus pathogenesis. J Virol 82:2040–2055. http://dx.doi.org/10
.1128/JVI.01625-07.
2. Committee on Infectious Diseases. 2009. From the American Academy
of Pediatrics: policy statements—modified recommendations for use of
palivizumab for prevention of respiratory syncytial virus infections. Pedi-
atrics 124:1694–1701. http://dx.doi.org/10.1542/peds.2009-2345.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005.
Respiratory syncytial virus infection in elderly andhigh-risk adults.NEngl
J Med 352:1749–1759. http://dx.doi.org/10.1056/NEJMoa043951.
4. van Drunen Littel-van den Hurk S, Watkiss ER. 2012. Pathogenesis of
respiratory syncytial virus. Curr Opin Virol 2:300–305. http://dx.doi.org
/10.1016/j.coviro.2012.01.008.
5. MacLellan K, Loney C, Yeo R, Bhella D. 2007. The 24-angstrom struc-
ture of respiratory syncytial virus nucleocapsid protein-RNA decameric
rings. J Virol 81:9519–9524. http://dx.doi.org/10.1128/JVI.00526-07.
6. Collins PL, Melero JA. 2011. Progress in understanding and controlling
respiratory syncytial virus: still crazy after all these years. Virus Res 162:
80–99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
7. Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus:
virology, reverse genetics, and pathogenesis of disease. Curr Top Mi-
crobiol Immunol 372:3–38. http://dx.doi.org/10.1007/978-3-642
-38919-1_1.
8. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L,
Castagne N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eleouet
JF, Rey FA. 2009. Crystal structure of a nucleocapsid-like nucleoprotein-
RNA complex of respiratory syncytial virus. Science 326:1279–1283. http:
//dx.doi.org/10.1126/science.1177634.
9. Mazumder B, Barik S. 1994. Requirement of casein kinase II-mediated
phosphorylation for the transcriptional activity of human respiratory syn-
cytial viral phosphoprotein P: transdominant negative phenotype of phos-
phorylation-defective P mutants. Virology 205:104–111. http://dx.doi
.org/10.1006/viro.1994.1624.
10. Noton SL, Deflube LR, Tremaglio CZ, Fearns R. 2012. The respiratory
syncytial virus polymerase has multiple RNA synthesis activities at the
promoter. PLoS Pathog 8:e1002980. http://dx.doi.org/10.1371/journal
.ppat.1002980.
11. Fearns R, Collins PL. 1999. Role of the M2-1 transcription antitermina-
tion protein of respiratory syncytial virus in sequential transcription. J
Virol 73:5852–5864.
12. Collins PL, Hill MG, Cristina J, Grosfeld H. 1996. Transcription elon-
gation factor of respiratory syncytial virus, a nonsegmented negative-
strand RNA virus. Proc Natl Acad Sci U S A 93:81–85. http://dx.doi.org
/10.1073/pnas.93.1.81.
13. Galloux M, Tarus B, Blazevic I, Fix J, Duquerroy S, Eleouet JF. 2012.
Characterization of a viral phosphoprotein binding site on the surface of
the respiratory syncytial nucleoprotein. J Virol 86:8375–8387. http://dx
.doi.org/10.1128/JVI.00058-12.
14. Noton SL, Fearns R. 2015. Initiation and regulation of paramyxovirus
transcription and replication. Virology 479–480:545–554. http://dx.doi
.org/10.1016/j.virol.2015.01.014.
15. Collins PL, Dickens LE, Buckler-White A, Olmsted RA, Spriggs MK,
Camargo E, Coelingh KV. 1986. Nucleotide sequences for the gene junc-
tions of human respiratory syncytial virus reveal distinctive features of
intergenic structure and gene order. Proc Natl Acad Sci U S A 83:4594–
4598. http://dx.doi.org/10.1073/pnas.83.13.4594.
16. Kuo L, Grosfeld H, Cristina J, Hill MG, Collins PL. 1996. Effects of
mutations in the gene-start and gene-end sequence motifs on transcrip-
tion of monocistronic and dicistronic minigenomes of respiratory syncy-
tial virus. J Virol 70:6892–6901.
17. Dickens LE, Collins PL, Wertz GW. 1984. Transcriptional mapping of
human respiratory syncytial virus. J Virol 52:364–369.
18. Tremaglio CZ, Noton SL, Deflube LR, Fearns R. 2013. Respiratory
syncytial virus polymerase can initiate transcription fromposition 3 of the
leader promoter. J Virol 87:3196–3207. http://dx.doi.org/10.1128/JVI
.02862-12.
19. Barik S. 1992. Transcription of human respiratory syncytial virus genome
RNA in vitro: requirement of cellular factor(s). J Virol 66:6813–6818.
20. Chu HY, Englund JA. 2013. Respiratory syncytial virus disease: preven-
tion and treatment. Curr TopMicrobiol Immunol 372:235–258. http://dx
.doi.org/10.1007/978-3-642-38919-1_12.
21. Waghmare A, Campbell AP, Xie H, Seo S, Kuypers J, Leisenring W,
Jerome KR, Englund JA, Boeckh M. 2013. Respiratory syncytial virus
lower respiratory disease in hematopoietic cell transplant recipients: viral
RNA detection in blood, antiviral treatment, and clinical outcomes. Clin
Infect Dis 57:1731–1741. http://dx.doi.org/10.1093/cid/cit639.
22. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J,
Radenne S, Coilly A, Garrigue V, D’Alteroche L, Buchler M, Couzi L,
Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM,
Abravanel F, Pol S, Rostaing L, Mallet V. 2014. Ribavirin for chronic
hepatitis E virus infection in transplant recipients. N Engl J Med 370:
1111–1120. http://dx.doi.org/10.1056/NEJMoa1215246.
23. Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW,
Fuller C, Daumer M, Teuber G, Wedemeyer H, Berg T, Lengauer T,
Zeuzem S, Herrmann E, Sarrazin C. 2013. Deep sequencing reveals
mutagenic effects of ribavirin during monotherapy of hepatitis C virus
genotype 1-infected patients. J Virol 87:6172–6181. http://dx.doi.org
/10.1128/JVI.02778-12.
24. Soares-Weiser K, Thomas S, Thomson G, Garner P. 2010. Ribavirin for
Crimean-Congo hemorrhagic fever: systematic review andmeta-analysis.
BMC Infect Dis 10:207. http://dx.doi.org/10.1186/1471-2334-10-207.
25. Willis RC, Carson DA, Seegmiller JE. 1978. Adenosine kinase initiates
the major route of ribavirin activation in a cultured human cell line. Proc
Natl Acad Sci U S A 75:3042–3044. http://dx.doi.org/10.1073/pnas.75.7
.3042.
26. Zimmerman TP, Deeprose RD. 1978. Metabolism of 5-amino-1-beta-
D-ribofuranosylimidazole-4-carboxamide and related five-membered
heterocycles to 5=-triphosphates in human blood and L5178Y cells.
Biochem Pharmacol 27:709 –716. http://dx.doi.org/10.1016/0006
-2952(78)90508-7.
27. Dixit NM, Perelson AS. 2006. The metabolism, pharmacokinetics and
mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell
Mol Life Sci 63:832–842. http://dx.doi.org/10.1007/s00018-005-5455-y.
28. Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against
distinct viruses. Rev Med Virol 16:37–48. http://dx.doi.org/10.1002/rmv
.483.
29. Paeshuyse J, Dallmeier K, Neyts J. 2011. Ribavirin for the treatment of
chronic hepatitis C virus infection: a review of the proposed mechanisms
of action. Curr Opin Virol 1:590–598. http://dx.doi.org/10.1016/j.coviro
.2011.10.030.
30. Cameron CE, Castro C. 2001. The mechanism of action of ribavirin:
lethal mutagenesis of RNA virus genomes mediated by the viral RNA-
dependent RNA polymerase. Curr Opin Infect Dis 14:757–764.
RNA-seq Analysis of HRSV
May 2016 Volume 90 Number 10 jvi.asm.org 4887Journal of Virology
31. Vignuzzi M, Stone JK, Andino R. 2005. Ribavirin and lethal mutagenesis
of poliovirus: molecular mechanisms, resistance and biological implica-
tions. Virus Res 107:173–181. http://dx.doi.org/10.1016/j.virusres.2004
.11.007.
32. Vo NV, Young KC, Lai MM. 2003. Mutagenic and inhibitory effects of
ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42:10462–
10471. http://dx.doi.org/10.1021/bi0344681.
33. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe:
directmolecular test by using ribavirin. ProcNatl Acad Sci U SA 98:6895–
6900. http://dx.doi.org/10.1073/pnas.111085598.
34. Smee DF, Matthews TR. 1986. Metabolism of ribavirin in respiratory
syncytial virus-infected and uninfected cells. Antimicrob Agents Che-
mother 30:117–121. http://dx.doi.org/10.1128/AAC.30.1.117.
35. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant
mechanism by which ribavirin exerts its antiviral activity in vitro against
flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehy-
drogenase. J Virol 79:1943–1947. http://dx.doi.org/10.1128/JVI.79.3.1943
-1947.2005.
36. Topfer A, Zagordi O, Prabhakaran S, Roth V, Halperin E, Beerenwinkel
N. 2013. Probabilistic inference of viral quasispecies subject to recombi-
nation. J Comput Biol 20:113–123. http://dx.doi.org/10.1089/cmb.2012
.0232.
37. Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Ram-
baut A, Hewson R, Garcia-Dorival I, Bore JA, Koundouno R, Abdellati
S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Ba-
dusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B,
Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti
F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour
S, Ehichioya D, Ellerbrok H, Fenandez-Garcia MD, Fizet A, Fleis-
chmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U,
Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva
M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes
P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J,
Molkenthin P, Muñoz-Fontela C, Muth D, Newman EN, Ngabo D,
Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E,
Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe
J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G,
Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Ver-
moesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR,
Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CE,
Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de
Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK,
Koivogui L, Magassouba N, Avšicˇ-Županc T, Nitsche A, Strasser M,
Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A,
Wölfel R, Formenty P, Günther S. 2015. Temporal and spatial analysis of
the 2014-2015 Ebola virus outbreak in West Africa. Nature 524:97–101.
http://dx.doi.org/10.1038/nature14594.
38. Hruska JF, Bernstein JM, Douglas RG, Jr, Hall CB. 1980. Effects of
ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Che-
mother 17:770–775. http://dx.doi.org/10.1128/AAC.17.5.770.
39. Dowall SD, Matthews DA, Garcia-Dorival I, Taylor I, Kenny J, Hertz-
Fowler C, Hall N, Corbin-Lickfett K, Empig C, Schlunegger K, Barr JN,
Carroll MW, Hewson R, Hiscox JA. 2014. Elucidating variations in the
nucleotide sequence of Ebola virus associated with increasing pathogenic-
ity. Genome Biol 15:540. http://dx.doi.org/10.1186/s13059-014-0540-x.
40. Cartee TL, Megaw AG, Oomens AGP, Wertz GW. 2003. Identification of
a single amino acid change in the human respiratory syncytial virus L
protein that affects transcriptional termination. J Virol 77:7352–7360.
http://dx.doi.org/10.1128/JVI.77.13.7352-7360.2003.
41. Wynne JW, Shiell BJ, Marsh GA, Boyd V, Harper JA, Heesom K,
Monaghan P, Zhou P, Payne J, Klein R, Todd S, Mok L, Green D,
Bingham J, Tachedjian M, Baker ML, Matthews D, Wang LF. 2014.
Proteomics informed by transcriptomics reveals Hendra virus sensitizes
bat cells to TRAIL mediated apoptosis. Genome Biol 15:532.
42. Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O,
Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de
Oliveira AP, Simabuco FM, Ventura AM, Hughes DJ, Barr JN, Fearns
R, Digard P, Eleouet JF, Hiscox JA. 2015. Interactome analysis of the
human respiratory syncytial virus RNA polymerase complex identifies
protein chaperones as important cofactors that promote L-protein stabil-
ity and RNA synthesis. J Virol 89:917–930. http://dx.doi.org/10.1128/JVI
.01783-14.
43. Geller R, Andino R, Frydman J. 2013. Hsp90 inhibitors exhibit resis-
tance-free antiviral activity against respiratory syncytial virus. PLoS One
8:e56762. http://dx.doi.org/10.1371/journal.pone.0056762.
44. Radhakrishnan A, Yeo D, Brown G, Myaing MZ, Iyer LR, Fleck R,
Tan BH, Aitken J, Sanmun D, Tang K, Yarwood A, Brink J, Sugrue
RJ. 2010. Protein analysis of purified respiratory syncytial virus parti-
cles reveals an important role for heat shock protein 90 in virus particle
assembly. Mol Cell Proteomics 9:1829–1848. http://dx.doi.org/10
.1074/mcp.M110.001651.
45. Connor JH, McKenzie MO, Parks GD, Lyles DS. 2007. Antiviral activity
and RNA polymerase degradation following Hsp90 inhibition in a range
of negative strand viruses. Virology 362:109–119. http://dx.doi.org/10
.1016/j.virol.2006.12.026.
46. Anderson JP, Daifuku R, Loeb LA. 2004. Viral error catastrophe by
mutagenic nucleosides. Annu Rev Microbiol 58:183–205. http://dx.doi
.org/10.1146/annurev.micro.58.030603.123649.
47. Drake JW. 1993. Rates of spontaneous mutation among RNA viruses.
Proc Natl Acad Sci U S A 90:4171–4175. http://dx.doi.org/10.1073/pnas
.90.9.4171.
48. Crotty S, Andino R. 2002. Implications of high RNA virusmutation rates:
lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect
4:1301–1307. http://dx.doi.org/10.1016/S1286-4579(02)00008-4.
49. Crotty S, Cameron C, Andino R. 2002. Ribavirin’s antiviral mechanism
of action: lethal mutagenesis? J Mol Med (Berl) 80:86–95. http://dx.doi
.org/10.1007/s00109-001-0308-0.
50. Samuel CE. 2011. Adenosine deaminases acting on RNA (ADARs) are
both antiviral and proviral. Virology 411:180–193. http://dx.doi.org/10
.1016/j.virol.2010.12.004.
51. Stark JM, Barmada MM, Winterberg AV, Majumber N, Gibbons WJ, Jr,
Stark MA, Sartor MA, Medvedovic M, Kolls J, Bein K, Mailaparambil
B, Krueger M, Heinzmann A, Leikauf GD, Prows DR. 2010. Genome-
wide association analysis of respiratory syncytial virus infection in mice. J
Virol 84:2257–2269. http://dx.doi.org/10.1128/JVI.00584-09.
52. Martinez I, Melero JA. 2002. A model for the generation of multiple A to
G transitions in the human respiratory syncytial virus genome: predicted
RNA secondary structures as substrates for adenosine deaminases that act
on RNA. J Gen Virol 83:1445–1455. http://dx.doi.org/10.1099/0022-1317
-83-6-1445.
Aljabr et al.
4888 jvi.asm.org May 2016 Volume 90 Number 10Journal of Virology
